121 related articles for article (PubMed ID: 21651645)
1. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Kamiya K; Watanabe M; Kohno M; Izumi Y; Horinouchi H; Kawamura M; Shimada N; Nomori H
Respirology; 2011 Aug; 16(6):976-82. PubMed ID: 21651645
[TBL] [Abstract][Full Text] [Related]
2. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
Qin HF; Qu LL; Liu H; Wang SS; Gao HJ
Asian Pac J Cancer Prev; 2013; 14(7):4205-8. PubMed ID: 23991977
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
Fujiwara Y; Kiura K; Toyooka S; Hotta K; Tabata M; Takigawa N; Soh J; Tanimoto Y; Kanehiro A; Kato K; Date H; Tanimoto M
Lung Cancer; 2008 Jan; 59(1):81-7. PubMed ID: 17765355
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jung M; Kim SH; Hong S; Kang YA; Kim SK; Chang J; Rha SY; Kim JH; Kim DJ; Cho BC
Yonsei Med J; 2012 Sep; 53(5):931-9. PubMed ID: 22869475
[TBL] [Abstract][Full Text] [Related]
6. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
[TBL] [Abstract][Full Text] [Related]
7. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
8. Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Zhuang J; Tang X; Du Z; Yang M; Zhou Y
Talanta; 2016 Nov; 160():636-644. PubMed ID: 27591660
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
[TBL] [Abstract][Full Text] [Related]
10. KL-6 and poor prognosis in NSCLC patients treated with gefitinib.
Ohara G; Kurishima K; Ishikawa H; Satoh H; Hizawa N
Lung Cancer; 2008 Jan; 59(1):138; author reply 139. PubMed ID: 18006181
[No Abstract] [Full Text] [Related]
11. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
12. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Xu CA; Su H; Liu JL; Li L; Zou HW
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
[TBL] [Abstract][Full Text] [Related]
13. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Ishikawa N; Daigo Y; Takano A; Taniwaki M; Kato T; Hayama S; Murakami H; Takeshima Y; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
Cancer Res; 2005 Oct; 65(20):9176-84. PubMed ID: 16230376
[TBL] [Abstract][Full Text] [Related]
14. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer.
Tanaka S; Hattori N; Ishikawa N; Shoda H; Takano A; Nishino R; Okada M; Arihiro K; Inai K; Hamada H; Yokoyama A; Kohno N
Int J Cancer; 2012 Jan; 130(2):377-87. PubMed ID: 21351094
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
16. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
Chiu CH; Shih YN; Tsai CM; Liou JL; Chen YM; Perng RP
Lung Cancer; 2007 Aug; 57(2):213-21. PubMed ID: 17449138
[TBL] [Abstract][Full Text] [Related]
17. Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer.
Hotta K; Kiura K; Tabata M; Takigawa N; Fujiwara Y; Umemura S; Tanimoto M
Anticancer Res; 2007; 27(3B):1737-41. PubMed ID: 17595807
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
[TBL] [Abstract][Full Text] [Related]
19. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Kanazawa S; Yamaguchi K; Kinoshita Y; Komiyama Y; Muramatsu M; Nomura S
J Cancer Res Clin Oncol; 2006 Nov; 132(11):719-25. PubMed ID: 16835747
[TBL] [Abstract][Full Text] [Related]
20. [Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].
Gu AQ; Wang HM; Shi CL; Xiong LW; Gao ZQ; Han BH
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):71-4. PubMed ID: 20211075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]